October 21, 2016 6:32 PM ET

Life Sciences Tools and Services

Company Overview of Oxford Gene Technology IP Limited

Company Overview

Oxford Gene Technology IP Limited provides genetics research and biomarker solutions to clinical and academic research institutions worldwide. Its products include Cytocell fluorescence in situ hybridisation probes for the detection of gene rearrangements related to inherited genetic disease and cancer; ovarian cancer, myeloid, and solid tumor panels; microarray and next generation sequencing library preparation kits; constitutional v3 and constitutional v3+LOH, medical research exome, autism research, NMD research, cardiomyopathy research, eye disease research, disease-focused research, and embryo screen arrays; and CytoSure international standards for cytogenomic arrays. It offers solution...

Begbroke Science Park

Begbroke Hill

Woodstock Road

Begbroke,  OX5 1PF

United Kingdom

Founded in 1995


44 1865 856800


44 1865 848684

Key Executives for Oxford Gene Technology IP Limited

Chief Executive Officer and Director
Age: 58
Founder, Chief Science Advisor and Director
Chief Financial Officer and Director
Age: 53
Executive Vice President of Group Operations and Cambridge Site Director
Executive Vice President of R&D
Compensation as of Fiscal Year 2016.

Oxford Gene Technology IP Limited Key Developments

Oxford Gene Technology Launches Two New CE-IVD Labelled Fluorescence in Situ Hybridisation Probes for Expanding Lung Cancer Portfolio

Oxford Gene Technology has launched two new CE-IVD labelled fluorescence in situ hybridisation (FISH) probes, further expanding its extensive lung cancer portfolio. The Cytocell Aquarius ROS1 Plus Breakapart and RET Breakapart probes specifically and accurately detect rearrangements in the genome associated with the most common form of lung cancer non-small cell lung cancer (NSCLC). The new additions complement OGT’s existing NSCLC probe range (including ALK Breakapart, EGFR Amplification and EML Breakapart), providing a comprehensive solution for diagnosis and patient stratification. The probes are available in two economical sizes and are premixed in hybridisation buffer — saving time and minimising potential errors. Fully optimised for use on formalin-fixed, paraffin-embedded (FFPE) samples, Cytocell FISH probes deliver high-intensity signals with minimal background for accurate, reliable results and confident diagnoses.

Oxford Gene Technology Launches 9 New Cytocell Aquarius® FISH Probes

Oxford Gene Technology has further expanded its extensive catalogue of fluorescence in situ hybridisation (FISH) products with 9 new Cytocell Aquarius ® probes. The range now includes ETV6 Proximal Probe Green, ETV6 Distal Probe Red, MPO Probe Red, TP53 Probe Green, NUP214 Probe Red, DEK Probe Green, TAS2R1 (5p15.31) Probe Green, Chromosome 9 Satellite III Probe Aqua and Chromosome 15 Alpha Satellite Probe Red. These cost-effective and quality-assured probes produce specific, high-intensity signals with excellent contrast and minimal background for the utmost confidence in results. Optimised for use on common sample types, the probes are also pre-mixed in hybridisation buffer, increasing ease of use and reducing errors in the laboratory. Highlighting OGT’s renowned customer service, the new additions to the range have been developed in response to high customer demand via the Cytocell myProbes ® FISH probes service. This custom probe design and manufacturing service enables OGT customers to purchase unique, fully quality-assured FISH probes for virtually any sequence in the entire human genome using the proprietary Cytocell BAC clone collection. The new additions to the Cytocell Aquarius ® probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.

Oxford Gene Technology Reports Revenue Results for the Fiscal 2015

Oxford Gene Technology reported revenue results for the fiscal 2015. Total revenue grew by 12% to £17.1 million despite divestments and anticipated fall in royalty income.

Similar Private Companies By Industry

Company Name Region
14M Genomics Ltd Europe
AB-Polyblok Ltd Europe
Abcellute Ltd. Europe
Ablatus Therapeutics Limited Europe
Accuro Biologics Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oxford Gene Technology IP Limited, please visit www.ogt.co.uk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.